Cabaletta Bio (CABA) Competitors $1.75 -0.60 (-25.53%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$1.74 -0.01 (-0.86%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. UPXI, BNTC, CMPS, HUMA, ERAS, ABVX, KMDA, PGEN, ZYBT, and MREOShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Upexi (UPXI), Benitec Biopharma (BNTC), COMPASS Pathways (CMPS), Humacyte (HUMA), Erasca (ERAS), ABIVAX Société Anonyme (ABVX), Kamada (KMDA), Precigen (PGEN), Zhengye Biotechnology (ZYBT), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Its Competitors Upexi Benitec Biopharma COMPASS Pathways Humacyte Erasca ABIVAX Société Anonyme Kamada Precigen Zhengye Biotechnology Mereo BioPharma Group Cabaletta Bio (NASDAQ:CABA) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has more risk and volatility, CABA or UPXI? Cabaletta Bio has a beta of 2.81, suggesting that its share price is 181% more volatile than the S&P 500. Comparatively, Upexi has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500. Which has preferable earnings & valuation, CABA or UPXI? Upexi has higher revenue and earnings than Cabaletta Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$67.68M-$2.54-0.69Upexi$16.56M29.10-$23.66MN/AN/A Does the media favor CABA or UPXI? In the previous week, Cabaletta Bio had 7 more articles in the media than Upexi. MarketBeat recorded 16 mentions for Cabaletta Bio and 9 mentions for Upexi. Cabaletta Bio's average media sentiment score of 0.63 beat Upexi's score of 0.42 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upexi 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in CABA or UPXI? Cabaletta Bio received 95 more outperform votes than Upexi when rated by MarketBeat users. Likewise, 73.13% of users gave Cabaletta Bio an outperform vote while only 37.50% of users gave Upexi an outperform vote. CompanyUnderperformOutperformCabaletta BioOutperform Votes9873.13% Underperform Votes3626.87% UpexiOutperform Votes337.50% Underperform Votes562.50% Is CABA or UPXI more profitable? Upexi's return on equity of 0.00% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -50.10% -45.49% Upexi N/A N/A N/A Do insiders & institutionals have more ownership in CABA or UPXI? 5.7% of Upexi shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by insiders. Comparatively, 31.6% of Upexi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend CABA or UPXI? Cabaletta Bio presently has a consensus price target of $20.33, indicating a potential upside of 1,061.90%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Cabaletta Bio is more favorable than Upexi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Upexi 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCabaletta Bio beats Upexi on 9 of the 15 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.80M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-0.8133.3227.1220.06Price / SalesN/A469.84412.30157.10Price / CashN/A168.6838.2534.64Price / Book0.323.457.064.70Net Income-$67.68M-$72.35M$3.23B$247.88M7 Day Performance-19.72%6.23%2.86%2.63%1 Month Performance35.66%16.53%9.07%6.36%1 Year Performance-85.61%-16.90%31.45%14.05% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio2.9066 of 5 stars$1.75-25.5%$20.33+1,061.9%-84.2%$88.80MN/A-0.8150Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeUPXIUpexi1.0865 of 5 stars$10.79+1.4%N/A+29.5%$407.78M$16.56M0.00130Short Interest ↑Gap UpBNTCBenitec Biopharma2.4109 of 5 stars$16.05+4.5%$24.71+54.0%+120.8%$406.91M$80K-10.5320CMPSCOMPASS Pathways2.653 of 5 stars$4.31+3.5%$18.83+337.5%-28.2%$402.78MN/A-1.96120Positive NewsHUMAHumacyte2.5248 of 5 stars$2.59-3.2%$11.71+353.2%-63.7%$402.53M$517K-1.94150Analyst ForecastAnalyst RevisionERASErasca2.7685 of 5 stars$1.41+0.4%$4.57+225.4%-32.4%$398.02MN/A-1.69120Positive NewsABVXABIVAX Société Anonyme1.9872 of 5 stars$6.26+4.0%$31.00+395.2%-47.3%$397.11MN/A0.0061Analyst RevisionGap DownKMDAKamada3.8274 of 5 stars$6.88+0.4%$14.67+113.3%+36.3%$395.23M$167.24M24.56360Positive NewsShort Interest ↑PGENPrecigen4.1585 of 5 stars$1.34+1.1%$7.00+424.3%-8.5%$394.07M$4.20M-2.43190Positive NewsAnalyst RevisionGap UpZYBTZhengye BiotechnologyN/A$8.26-8.4%N/AN/A$389.59M$189.75M0.00278Gap UpMREOMereo BioPharma Group1.747 of 5 stars$2.45+13.7%$7.71+215.5%-24.7%$385.58M$1M-34.6440Positive NewsAnalyst Revision Related Companies and Tools Related Companies UPXI Competitors BNTC Competitors CMPS Competitors HUMA Competitors ERAS Competitors ABVX Competitors KMDA Competitors PGEN Competitors ZYBT Competitors MREO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CABA Stock Free CABA Stock Alerts